1. Home
  2. GEVO vs CUVL Comparison

GEVO vs CUVL Comparison

Compare GEVO & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

N/A

Current Price

$1.81

Market Cap

343.7M

Sector

Industrials

ML Signal

N/A

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

SELL

Current Price

$5.14

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

SELL

Company Overview

Basic Information
Metric
GEVO
CUVL
Founded
2005
1999
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Chemicals
Miscellaneous
Sector
Industrials
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
343.7M
374.2M
IPO Year
2010
2004

Fundamental Metrics

Financial Performance
Metric
GEVO
CUVL
Price
$1.81
$5.14
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $5.11
N/A
AVG Volume (30 Days)
★ 4.4M
4.9K
Earning Date
11-10-2026
08-27-2026
Dividend Yield
N/A
★ 0.56%
EPS Growth
★ 58.82
N/A
EPS
N/A
★ N/A
Revenue
★ $711,000.00
N/A
Revenue This Year
$29.71
$0.47
Revenue Next Year
$2.42
$6.25
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.09
$4.81
52 Week High
$2.97
$8.20

Technical Indicators

Market Signals
Indicator
GEVO
CUVL
Relative Strength Index (RSI) 72.13 44.12
Support Level $1.62 $4.86
Resistance Level $1.91 $6.00
Average True Range (ATR) 0.12 0.26
MACD 0.08 0.05
Stochastic Oscillator 71.49 22.31

Price Performance

Historical Comparison
GEVO
CUVL

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: